Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

American Society of Clinical Oncology (ASCO) - Tập 22 Số 6 - Trang 1078-1086 - 2004
Peter L. Greenberg1, Sandra J. Lee1, Ranjana H. Advani1, Martin S. Tallman1, Branimir I. Šikić1, Louis Letendre1, Kathleen Dugan1, Bert L. Lum1, David L. Chin1, Gordon W. Dewald1, Elisabeth Paietta1, John M. Bennett1, Jacob M. Rowe1
1From the Stanford University Medical Center, Stanford; VA Palo Alto Health Care System, Palo Alto, CA; Dana- Farber Cancer Institute, Boston, MA; Northwestern University Feinberg School of Medicine, Chicago, IL; Mayo Clinic, Rochester, MN; Our Lady of Mercy Medical Center, Bronx; Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY; and Rambam Medical Center, Haifa, Israel

Tóm tắt

Purpose To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Patients and Methods A phase III randomized study was performed using valspodar plus mitoxantrone, etoposide, and cytarabine (PSC-MEC; n = 66) versus MEC (n = 63) to treat patients with relapsed or refractory AML and high-risk MDS. Results For the PSC-MEC versus MEC arms, complete response (CR) was achieved in 17% versus 25% of patients, respectively (P = not significant). For patients who had not received prior intensive chemotherapy (ie, with secondary AML or high-risk MDS), the CR rate was increased—35% versus 15% for the remaining patients (P = .018); CR rates did not differ between treatment arms. The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients’ overall survival (4.6 versus 5.4 months). The CR rates in MDR+ (69% of patients) versus MDR− patients were similar for those receiving either chemotherapy regimen (16% versus 24%). The CR rate for unfavorable cytogenetic patients (45% of patients) was 13% compared to the remainder, 28% (P = .09). Population pharmacokinetic analysis demonstrated that the clearances of mitoxantrone and etoposide were decreased by 59% and 50%, respectively, supporting the empiric dose reductions in the PSC-MEC arm designed in anticipation of drug interactions between valspodar and the chemotherapeutic agents. Conclusion CR rates and overall survival were not improved by using PSC-MEC compared to MEC chemotherapy alone in patients with poor-risk AML or high-risk MDS.

Từ khóa


Tài liệu tham khảo

10.1002/ajh.2830270315

10.1056/NEJM199909303411407

Lepelley P, Soenen V, Preudhomme C, et al: Expression of multi-drug resistance p-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 8:998,1994-1004,

List AF: Multidrug resistance: Clinical relevance in acute leukemia. Oncology 7:23,1993-28,

10.1182/blood.V81.9.2215.2215

10.1182/blood.V79.2.473.473

10.1182/blood.V78.3.586.586

10.1111/j.1365-2141.1994.tb08305.x

10.1182/blood.V82.10.3157.3157

10.1111/j.1365-2141.1991.tb04378.x

Leith C, Kopecky K, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of MDR-1 and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A SWOG study. Blood 89:3323,1997-3329,

10.1093/jnci/82.13.1133

10.1002/ijc.2910450210

10.1200/JCO.1992.10.11.1730

10.1200/JCO.1993.11.9.1652

10.1002/(SICI)1097-0142(19990115)85:2<358::AID-CNCR13>3.0.CO;2-0

10.1182/blood.V93.3.787

10.1016/0277-5379(91)90435-G

Boesh D, Gaveriaux C, Jachez B, et al: In vivo circumvention of P-glycoprotein-mediated multi drug resistance of tumor cells with SDZ PSC833. Cancer Res 51:4226,1991-4233,

10.1002/ijc.2910500418

10.1200/JCO.1996.14.2.610

10.1002/ijc.2910510316

Fisher GA, Lum BL, Hausdorff J, et al: Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 32A:1082,1996-1088,

10.1200/JCO.2001.19.6.1589

10.1182/blood.V89.6.2079

10.1016/0268-960X(95)90039-X

10.1007/BF02990947

S. Karger: Neoplasia. In Mitelman F (ed), An international system for human cytogenetic nomenclature . Basel, Switzerland, p 78,1995

10.1182/blood.V96.13.4075

10.1097/00007691-199308000-00011

10.1016/S0378-4347(00)83783-4

10.1097/00007691-199310000-00016

10.1016/S0378-4347(97)00543-4

10.1200/JCO.1992.10.10.1635

Beal SL, Sheiner LB: Methodology of population pharmacokinetics, in, Garrett ER, Hirtz J (eds), Drug Fate and Metabolism: Methods and Techniques, Vol 5 , New York, NY, Marcel Decker, pp 135,1985-183

10.1002/j.1552-4604.1988.tb05714.x

10.1200/JCO.1994.12.1.141

10.1097/00007691-200212000-00005

Agresti, A: Categorical Data Analysis . New York, NY, Wiley, pp 59,1990-66

10.1080/01621459.1958.10501452

Lehmann EL: Nonparametrics: Statistical methods based on ranks . Upper Saddle River, NJ, Prentice-Hall, pp 5,1998-12

10.1016/0378-3758(94)90187-2

10.1182/blood.V88.2.756.bloodjournal882756

10.1111/j.1365-2141.1990.tb04346.x

10.1182/blood.V85.1.186.bloodjournal851186

Beck WT, Grogan TM, Willman CL, et al: Methods to detect P-glycoprotein associated with multidrug resistance in patients’ tumors. Consensus recommendations. Cancer Res 56:3010,1996-3020,

10.1182/blood.V100.4.1224.h81602001224_1224_1232

10.1016/S0145-2126(02)00181-9

10.1046/j.1365-2141.1998.00870.x

Sikic BI: Pharmacologic approaches to reversing multidrug resistance. Semin Hemat 34:40,1997-47, (suppl 5)

List AF: Non-P-glycoprotein drug export mechanisms of multidrug resistance. Semin Hemat 34:20,1997-24, (suppl 5)

Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of expression of the multidrug resistance proteins MDR1, MRP1 and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 94:1086,1999-1099,

Cripe L, Tallman MS, Karanes C, et al: A phase II trial of Zosuquidar (LY335979), a modulator of P-glycoprotein activity plus daunorubicin and high dose cytarabine in patients with newly diagnosed secondary acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation or relapsed/refractory AML. Blood 98:595a,2001, (suppl 1)

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 22 Số 6

1078-1086

Thông tin tác giả